CL2013001564A1 - Metodo para tratar sobrepeso u obesidad que comprende administrar naltrexona y bupropion; metodo para incrementar la biodisponibilidad de naltrexona y bupropion en una terapia combinada; uso de naltrexona y bupropion para tratar sobrepeso u obesisdad e incrementar la biodisponibilidad de estos farmacos; composicion farmaceutica. - Google Patents

Metodo para tratar sobrepeso u obesidad que comprende administrar naltrexona y bupropion; metodo para incrementar la biodisponibilidad de naltrexona y bupropion en una terapia combinada; uso de naltrexona y bupropion para tratar sobrepeso u obesisdad e incrementar la biodisponibilidad de estos farmacos; composicion farmaceutica.

Info

Publication number
CL2013001564A1
CL2013001564A1 CL2013001564A CL2013001564A CL2013001564A1 CL 2013001564 A1 CL2013001564 A1 CL 2013001564A1 CL 2013001564 A CL2013001564 A CL 2013001564A CL 2013001564 A CL2013001564 A CL 2013001564A CL 2013001564 A1 CL2013001564 A1 CL 2013001564A1
Authority
CL
Chile
Prior art keywords
bupropion
naltrexone
bioavailability
obesity
increase
Prior art date
Application number
CL2013001564A
Other languages
English (en)
Spanish (es)
Inventor
Eduardo Dunayevich
Shawn Flanagan
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013001564(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of CL2013001564A1 publication Critical patent/CL2013001564A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CL2013001564A 2010-12-03 2013-05-31 Metodo para tratar sobrepeso u obesidad que comprende administrar naltrexona y bupropion; metodo para incrementar la biodisponibilidad de naltrexona y bupropion en una terapia combinada; uso de naltrexona y bupropion para tratar sobrepeso u obesisdad e incrementar la biodisponibilidad de estos farmacos; composicion farmaceutica. CL2013001564A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41939510P 2010-12-03 2010-12-03

Publications (1)

Publication Number Publication Date
CL2013001564A1 true CL2013001564A1 (es) 2014-05-02

Family

ID=46172304

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013001564A CL2013001564A1 (es) 2010-12-03 2013-05-31 Metodo para tratar sobrepeso u obesidad que comprende administrar naltrexona y bupropion; metodo para incrementar la biodisponibilidad de naltrexona y bupropion en una terapia combinada; uso de naltrexona y bupropion para tratar sobrepeso u obesisdad e incrementar la biodisponibilidad de estos farmacos; composicion farmaceutica.

Country Status (27)

Country Link
US (1) US20130245056A1 (enExample)
EP (5) EP4349369B1 (enExample)
JP (4) JP6008866B2 (enExample)
KR (5) KR102391511B1 (enExample)
CN (1) CN103313711A (enExample)
AR (2) AR093182A1 (enExample)
AU (2) AU2011336304B2 (enExample)
BR (1) BR112013013390A2 (enExample)
CA (2) CA2819262C (enExample)
CL (1) CL2013001564A1 (enExample)
CY (2) CY1118968T1 (enExample)
DK (4) DK4349369T3 (enExample)
ES (3) ES2866879T3 (enExample)
FI (2) FI3884947T3 (enExample)
HR (4) HRP20251576T1 (enExample)
HU (3) HUE053831T2 (enExample)
IL (4) IL330443A (enExample)
LT (4) LT3222280T (enExample)
MX (2) MX384662B (enExample)
PL (4) PL3222280T3 (enExample)
PT (4) PT3222280T (enExample)
RS (4) RS67527B1 (enExample)
RU (1) RU2640561C2 (enExample)
SI (4) SI3222280T1 (enExample)
SM (4) SMT202100227T1 (enExample)
TW (1) TWI618536B (enExample)
WO (1) WO2012075459A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
PT3222280T (pt) * 2010-12-03 2021-04-22 Nalpropion Pharmaceuticals Llc Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
US20180015042A1 (en) * 2015-02-07 2018-01-18 Intas Pharmaceuticals Ltd. Pharmaceutical composition for the treatment of obesity
CA3083850A1 (en) * 2017-03-28 2019-10-04 LDN Pharma Limited An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer
EP3482751A1 (en) 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
EP1772147A2 (en) * 2003-03-17 2007-04-11 Japan Tobacco, Inc. Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
JP2009502931A (ja) 2005-07-27 2009-01-29 オレキシジェン・セラピューティクス・インコーポレーテッド 体重減少を促すための組成物
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
JP2009517393A (ja) 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
SI2484346T1 (sl) 2006-06-19 2017-05-31 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
KR101264789B1 (ko) 2006-06-30 2013-05-15 엘지디스플레이 주식회사 횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법
CA2693992C (en) * 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
DE602007005402D1 (de) * 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
WO2008060964A2 (en) * 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
KR20160065998A (ko) * 2007-04-11 2016-06-09 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
US8318813B2 (en) * 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
PT3222280T (pt) * 2010-12-03 2021-04-22 Nalpropion Pharmaceuticals Llc Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona

Also Published As

Publication number Publication date
PT3884947T (pt) 2024-02-16
US20130245056A1 (en) 2013-09-19
KR20200044158A (ko) 2020-04-28
RS65198B1 (sr) 2024-03-29
HUE034393T2 (en) 2018-02-28
EP2646031A4 (en) 2014-04-23
TW201304780A (zh) 2013-02-01
KR20140035320A (ko) 2014-03-21
MX356801B (es) 2018-06-13
CN103313711A (zh) 2013-09-18
JP7025319B2 (ja) 2022-02-24
EP3884947A1 (en) 2021-09-29
MX2013006071A (es) 2013-10-01
AR093182A1 (es) 2015-05-27
PL3884947T3 (pl) 2024-05-06
KR101984500B1 (ko) 2019-05-31
AU2011336304B2 (en) 2017-03-30
IL270841A (en) 2020-01-30
KR20210063473A (ko) 2021-06-01
DK3884947T3 (da) 2024-01-22
EP2646031B1 (en) 2017-02-22
DK4349369T3 (da) 2025-12-22
DK2646031T3 (en) 2017-05-22
EP3222280A1 (en) 2017-09-27
KR102105857B1 (ko) 2020-05-04
HUE053831T2 (hu) 2021-07-28
BR112013013390A2 (pt) 2016-09-06
CA2819262A1 (en) 2012-06-07
RU2640561C2 (ru) 2018-01-09
JP2013544290A (ja) 2013-12-12
HRP20251576T1 (hr) 2026-01-30
LT3884947T (lt) 2024-03-12
JP2019056004A (ja) 2019-04-11
EP4696322A3 (en) 2026-04-15
IL330443A (en) 2026-08-01
AU2011336304A1 (en) 2013-07-11
ES3056642T3 (en) 2026-02-23
JP6008866B2 (ja) 2016-10-19
SMT201700232T1 (it) 2017-07-18
EP4349369A2 (en) 2024-04-10
LT4349369T (lt) 2026-01-12
KR102258043B1 (ko) 2021-05-28
KR102391511B1 (ko) 2022-04-26
SI2646031T1 (sl) 2017-07-31
WO2012075459A1 (en) 2012-06-07
HRP20240115T1 (hr) 2024-06-07
KR20180069089A (ko) 2018-06-22
FI4349369T3 (fi) 2025-12-17
RU2017144631A3 (enExample) 2021-04-13
KR20190058702A (ko) 2019-05-29
SI3222280T1 (sl) 2021-11-30
IL226504B (en) 2021-01-31
EP3884947B1 (en) 2023-11-15
ES2866879T3 (es) 2021-10-20
HRP20210618T1 (hr) 2021-09-17
JP2022060331A (ja) 2022-04-14
PL3222280T3 (pl) 2021-11-29
CA3239386A1 (en) 2012-06-07
LT2646031T (lt) 2017-06-26
JP2016210809A (ja) 2016-12-15
PT4349369T (pt) 2025-12-17
HUE065852T2 (hu) 2024-06-28
EP4696322A2 (en) 2026-02-18
ES2625527T9 (es) 2018-09-25
SMT202400038T1 (it) 2024-03-13
EP4349369B1 (en) 2025-09-17
CA2819262C (en) 2024-05-28
SI4349369T1 (sl) 2026-02-27
ES2625527T3 (es) 2017-07-19
CY1118968T1 (el) 2018-01-10
PL2646031T3 (pl) 2017-08-31
RS56014B1 (sr) 2017-09-29
FI3884947T3 (fi) 2024-01-30
EP2646031B9 (en) 2018-01-10
SMT202500474T1 (it) 2026-01-12
TWI618536B (zh) 2018-03-21
RU2013127423A (ru) 2015-01-10
PT2646031T (pt) 2017-05-25
JP2024071605A (ja) 2024-05-24
PT3222280T (pt) 2021-04-22
RS67527B1 (sr) 2026-01-30
AU2017204309A1 (en) 2017-07-13
EP2646031A1 (en) 2013-10-09
MX384662B (es) 2025-03-14
RU2017144631A (ru) 2019-02-18
SI3884947T1 (sl) 2024-06-28
EP3222280B1 (en) 2021-01-20
CY1124331T1 (el) 2022-07-22
EP4349369A3 (en) 2024-05-15
RS62149B1 (sr) 2021-08-31
AR124500A2 (es) 2023-04-05
JP6456890B2 (ja) 2019-01-23
LT3222280T (lt) 2021-05-10
DK3222280T3 (da) 2021-04-19
IL279626A (en) 2021-03-01
PL4349369T3 (pl) 2026-03-23
HRP20170734T1 (hr) 2017-08-11
SMT202100227T1 (it) 2021-07-12

Similar Documents

Publication Publication Date Title
BR112013011480A2 (pt) método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer
IL274602A (en) Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and use thereof in the preparation of medicaments for treating thrombocytopenia
IL216668A (en) Pharmaceutical composition and use thereof for preparation of a medicament for emergency contraception
CL2014001450A1 (es) Forma de dosis de liberacion controlada solida que comprende un analgesico opioide dispersado en un material de matriz; metodo de preparacion; uso en el tratamiento del dolor.
BRPI1016147A2 (pt) sistema intrauterino para uso no tratamento de uma condição médica, e, método para a fabricação de um sistema intrauterino
ES2542042R1 (es) Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
AR078247A1 (es) Vacuna de pcsk9
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
CL2011002248A1 (es) Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor.
BRPI1007636A2 (pt) Composição farmacêutica, forma de dosagem, método para a preparação da composição farmacêutica, método de preparação da forma de dosagem e método de tratamento da dor
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
CL2013000481A1 (es) Metodo y para mejorar la eficacia y/o reducir los efectos secundarios de una farmacoterapia administrada de forma suboptima que comprende la administracion de un hexitol sustituido; composicion farmaceutica; combinacion farmaceutica; uso para tratar enfermedades proliferativas.
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
CL2012000319A1 (es) Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística.
CL2011002595A1 (es) Uso de una combinacion de un agente anticancerigeno y un antioxidante para tratar el cancer; y compicicion farmaceutica que comprende dicha combinacion.
IL211842A (en) Antibodies or fragments of their human tgfbrii, pharmacological preparations containing them and their use in the preparation of a drug for inhibiting anogenesis
CL2013000444A1 (es) Composicion farmaceutica oral de liberacion prolongada que comprende un material de liberacion prolongada, y oxicodona y naloxona, cuya composicion farmaceutica almacenada en condiciones de estres tiene menos de un 4% de sustancias relacionadas con oxicodona y naloxona; y uso de un aglutinante para fabricar dicha composicion.
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
BRPI1009781A2 (pt) compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona